Cardiovascular drugs and therapySep 1, 2026

Empagliflozin may reduce artery plaque by boosting cell cleanup in blood vessel lining

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 2, 2026

Abstract

Empagliflozin (EMPA) may influence the progression of atherosclerosis.

Mitophagy in endothelial cells may be promoted by EMPA.
Atherosclerosis progression is associated with cellular health in endothelial cells.
The study aims to explore the potential of EMPA in delaying atherosclerosis.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly Longevity & Aging Brief

You found one interesting study. We’ll send the next 7.

Get 7 new longevity & aging papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the longevity & aging brief

Your biological age can reverse — but scientists are still debating what that actually means

1 week ago7 studies

Deleting a DNA-sensing protein accelerates aging in mice — the opposite of what scientists expected

2 weeks ago6 studies

A cancer drug already in clinics may slow aging by quieting a key inflammatory signal

3 weeks ago7 studies

Senescent brain cells linked to age-related myelin loss via a newly identified signaling molecule

4 weeks ago7 studies

One month of vegan eating left measurable epigenetic marks on biological aging clocks

5 weeks ago7 studies

Mitochondrial metabolism secretly controls how inflammatory senescent cells actually get loud

6 weeks ago7 studies

Cutting one amino acid from mice's diet extended male lifespan by 23%

7 weeks ago7 studies

Vitamin C cut 4 years off primate bone marrow's biological age in a new study

8 weeks ago7 studies

Sweetened drinks are linked to faster biological aging, especially if you're under 55

9 weeks ago7 studies

Stress ages your blood stem cells — and the gut microbiome is the middleman

10 weeks ago7 studies

explore the archive

See more issues from the longevity & aging brief